Cargando…
Interplay of Extracellular Vesicles and TLR4 Signaling in Hepatocellular Carcinoma Pathophysiology and Therapeutics
Hepatocellular carcinoma (HCC) stands as a significant contributor to global cancer-related mortality. Chronic inflammation, often arising from diverse sources such as viral hepatitis, alcohol misuse, nonalcoholic fatty liver disease (NAFLD), and nonalcoholic steatohepatitis (NASH), profoundly influ...
Autores principales: | Papadakos, Stavros P., Arvanitakis, Konstantinos, Stergiou, Ioanna E., Vallilas, Christos, Sougioultzis, Stavros, Germanidis, Georgios, Theocharis, Stamatios |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10610499/ https://www.ncbi.nlm.nih.gov/pubmed/37896221 http://dx.doi.org/10.3390/pharmaceutics15102460 |
Ejemplares similares
-
The Role of TLR4 in the Immunotherapy of Hepatocellular Carcinoma: Can We Teach an Old Dog New Tricks?
por: Papadakos, Stavros P., et al.
Publicado: (2023) -
Unveiling the Yin-Yang Balance of M1 and M2 Macrophages in Hepatocellular Carcinoma: Role of Exosomes in Tumor Microenvironment and Immune Modulation
por: Papadakos, Stavros P., et al.
Publicado: (2023) -
Meeting at the Crossroad between Obesity and Hepatic Carcinogenesis: Unique Pathophysiological Pathways Raise Expectations for Innovative Therapeutic Approaches
por: Arvanitakis, Konstantinos, et al.
Publicado: (2023) -
Unraveling the Significance of EPH/Ephrin Signaling in Liver Cancer: Insights into Tumor Progression and Therapeutic Implications
por: Papadakos, Stavros P., et al.
Publicado: (2023) -
How Far beyond Diabetes Can the Benefits of Glucagon-like Peptide-1 Receptor Agonists Go? A Review of the Evidence on Their Effects on Hepatocellular Carcinoma
por: Arvanitakis, Konstantinos, et al.
Publicado: (2022)